ALA updated investor presentation
Our biotech Investment Arovella Therapeutics (ASX: ALA) just released an updated investor presentation.
Here are some slides that stood out to us:
1) On ALA’s partnership with $451M Imugene - In vivo data is due this half, meaning we could see the data from animal studies very soon.
2) ALA’s pathway to phase 1 firsts-in-human clinical trials in 2024 - this is significant especially because most cell therapy companies either do a deal or are acquired as they transition out of the pre-clinical stage.
![ALA slide 2](https://sdcms-prod.s3.ap-southeast-2.amazonaws.com/images/ALA_slide_2.width-800.png)
Here is a slide showing some deals in the cell therapy industry - almost all of them are done at the pre-clinical/phase 1 stage.
Interestingly the most recent one was done between Precision Biosciences and Imugene which has already got an existing partnership with ALA in place.
![ALA Slide 3](https://sdcms-prod.s3.ap-southeast-2.amazonaws.com/images/ALA_Slide_3.width-800.png)
To check out the updated investor presentation click here or on the image below:
![ALA Slide 4](https://sdcms-prod.s3.ap-southeast-2.amazonaws.com/images/ALA_Slide_4.width-800.png)